Silke Schirrmacher-Memmel

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg, Walter L. Vervenne, Maria De Santis et al. · European Urology · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Maurice Stephan Michel, Walter L. Vervenne, Maria De Santis et al. · Journal of Clinical Oncology · 2014 · 44 citations

Medicine, Oncology, Pharmacotherapy +17

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study

Alexander Stein, Julia Quidde, Jan Schröder et al. · BMC Cancer · 2016 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Peter J. Goebell, Walter L. Vervenne, Maria De Santis et al. · Journal of Clinical Oncology · 2014 · 12 citations

Medicine, Oncology, Pharmacology +15

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.

Maurice Stephan Michel, Walter L. Vervenne, Peter J. Goebell et al. · Journal of Clinical Oncology · 2012 · 10 citations

Medicine, Oncology, Pharmacotherapy +17